XML 45 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1
License, Collaboration and Service Agreements - Additional Information (Detail)
$ / shares in Units, £ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 15, 2021
USD ($)
Jun. 30, 2017
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2016
GBP (£)
May 31, 2016
USD ($)
Jun. 30, 2024
USD ($)
$ / shares
Mar. 31, 2024
USD ($)
Jun. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Jun. 30, 2024
USD ($)
$ / shares
shares
Jun. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
Sep. 30, 2023
USD ($)
Jul. 31, 2023
USD ($)
Nov. 07, 2022
USD ($)
Oct. 31, 2017
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Common stock, par value | $ / shares           $ 0.001             $ 0.001   $ 0.001          
Revenue recognized           $ 114,000   $ 269,000         $ 254,000 $ 492,000            
Milestone payment           225,000,000             225,000,000              
Total Milestone                             $ 95,000,000          
Deferred revenue, current           3,663,000             3,663,000   2,132,000          
GSK SPA [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Remaining transaction price allocated to the performance obligations           64,700,000             64,700,000              
Milestone payment           21,200,000             21,200,000              
Total Milestone           30,000,000             30,000,000              
Initial Payments to Perform the Obligations                               $ 66,000,000        
Discount on Obligations                               1,300,000        
GSK SPA [Member] | Research And Development Services Related To Upcoming Milestones [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Revenue recognized                               19,000,000        
GSK SPA [Member] | License and Know-How Transfer [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Remaining transaction price allocated to the performance obligations                               64,700,000        
Performance Obligation Allocated Transaction Price                               45,700,000        
Vertex License Agreement [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
License agreement research and development expense related to achievement of regulatory milestones                         $ 0 0            
Contract termination period                         10 years              
Nonrefundable upfront payments         $ 500,000                              
Potential milestone payment upon achievement of specified clinical, regulatory and commercial milestones         $ 80,200,000                              
Contract termination period if no material development or commercialization occurs                         1 year              
GSK License Agreement [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Performance Obligation Allocated Transaction Price           5,900,000   500,000         $ 10,000,000 1,000,000            
Deferred revenue, current           38,600,000             38,600,000              
GSK License Agreement [Member] | Research And Development Services Related To Upcoming Milestones [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Total potential additional milestones                             3,200,000          
GSK License Agreement [Member] | Glaxo Smith Kline [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Milestone payment           23,800,000             23,800,000   23,800,000       $ 66,000,000  
Reduction In Subsequent Payments by GSK to the Company                                     50.00%  
GSK License Agreement [Member] | Glaxo Smith Kline [Member] | Amendment 2 [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Milestone payment           1,200,000             1,200,000         $ 4,300,000    
GSK License Agreement [Member] | GSK SPA [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Milestone payment           23,800,000             23,800,000   64,700,000     $ 30,000,000    
Total Received Milestone                             95,000,000   $ 30,000,000      
Significant financing component                             2,500,000          
Total Milestone                             95,000,000          
Research and development services performance obligation           8,800,000             8,800,000   2,500,000          
Meiji License Agreement [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Nonrefundable upfront payments   $ 600,000                                    
Sublicense fee payable to counter party                               7,500,000        
Potential milestone payments upon achievement of specified condition                                       $ 1,000,000
License agreement fixed assets related payments                       $ 1,600,000                
Potential milestone payments upon completion and delivery of results of a clinical study             $ 1,000,000                          
Future milestone payments                         1,000,000              
Sublicence Fee Paid to Counter Party                               $ 6,600,000        
Remaining Sublicence Fee Paid to Counter Party                             $ 900,000          
Cantab Related Agreements [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Potential milestone payment upon achievement of specified commercial milestone       £ 5.0                 6,300,000              
License agreement research and development expense related to achievement of regulatory milestones                         $ 0 0            
Potential milestone payment upon achievement of specified clinical, regulatory and commercial milestones     $ 5,800,000                                  
Everest License Agreement [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Period of option granted on an agreement                         12 months              
Upfront payment received                     $ 3,000,000                  
Potential milestone payments upon completion and delivery of results of a clinical study                   $ 2,000,000                    
Revenue recognized           0   0         $ 0              
Milestone payment           34,000,000             34,000,000              
Everest License Agreement [Member] | SPR 206 [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Upfront payment received                     2,000,000                  
Milestones payment received $ 2,000,000                                      
Everest License Agreement [Member] | SPR 741 [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Upfront payment received                     $ 1,000,000                  
Everest License Agreement [Member] | Maximum [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Agreement termination period upon written notice 180 days                                      
Everest License Agreement [Member] | Maximum [Member] | SPR 206 [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Receivable amount upon achievement of certain milestone $ 38,000,000         59,500,000             $ 59,500,000              
Everest License Agreement [Member] | Minimum [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Agreement termination period upon written notice 90 days                                      
Pfizer License and Share Purchase Agreements [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Receivable amount upon achievement of certain milestone                 $ 900,000                      
Milestones payment received                 5,000,000                      
Issuance of stock, shares | shares                         2,362,348              
Issuance of stock, value                         $ 27,500,000              
Remaining transaction price allocated to the performance obligations           12,500,000             12,500,000              
Revenue recognized           100,000   $ 300,000         300,000 $ 500,000            
Premium associated freestanding equity                         12,500,000              
Performance Obligation Allocated Transaction Price                 5,000,000                      
Deferred revenue, current           $ 12,700,000             12,700,000              
Pfizer License and Share Purchase Agreements [Member] | SPR 206 [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Receivable amount upon achievement of certain milestone                         $ 80,000,000              
Issuance of stock, shares | shares                         2,362,348              
Share price | $ / shares           $ 16.93             $ 16.93              
Proceeds from sale of common stock to related party                         $ 40,000,000              
Pfizer License and Share Purchase Agreements [Member] | Research And Development Services Related To Upcoming Milestones [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Performance Obligation Allocated Transaction Price                 $ 4,100,000       11,100,000              
Pfizer License and Share Purchase Agreements [Member] | License and Know-How Transfer [Member]                                        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                                        
Performance Obligation Allocated Transaction Price                         $ 1,400,000